Alzental 20 mg/ml susp 20 ml

Alzental 20 mg / ml Albendazole micronized Oral Suspension 20 ml

Composition:

Each 1 ml suspension contains:

Albendazole micronized 20 mg

Therapeutic Indications:

Hydatid Disease (Echinococcosis: Alzental is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

Neurocysticercosis: Alzental is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

It is also used for:

Alzental is used in the treatment of single and mixed intestinal nematode infections including ascariasis, enterobiasis, hookworm, strongyloidiasis, and trichuriasis.

Alzental is indicated for the treatment of giardiasis.

Alzental is indicated for the treatment of capillariasis, gnathostomiasis, trichostrongyliasis.

Alzental is indicated for the treatment of lymphatic filariasis.

Warnings and Precautions:

-Bone Marrow Suppression:

Fatalities associated with the use of albendazole have been reported due to granulocytopenia or pancytopenia. Albendazole may cause bone marrow suppression, aplastic anemia, and agranulocytosis. Monitor blood counts at the beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy with albendazole in all patients. 

Patients with liver disease and patients with hepatic echinococcosis are at increased risk for bone marrow suppression and warrant more frequent monitoring of blood counts.

Discontinue albendazole, if clinically significant decreases in blood cell counts occur.

-Teratogenic Effects:

Albendazole may cause fetal harm and should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate.

-Risk of Neurologic Symptoms in Neurocysticercosis:

Patients being treated for neurocysticercosis should receive steroid and anticonvulsant therapy to prevent neurological symptoms e.g. seizures, increased intracranial pressure and focal signs) as a result of an inflammatory reaction caused by death of the parasite within the brain.

-Risk of Retinal Damage in Patients with Retinal Neurocysticercosis: Cysticercosis may involve the retina. Before initiating therapy for neurocysticercosis, examine the patient for the presence of retinal lesions. 

-Hepatic Effects: In clinical trials, treatment with albendazole has been associated with mild to moderate elevations of hepatic enzymes in approximately 16% of patients. These elevations have generally returned to normal upon discontinuation of therapy. 

Pregnancy and Lactation:

Pregnancy: Alzental should be used during pregnancy, only if the potential benefit justifies the potential risk to the fetus.

Lactation: 

Because many drugs are excreted in human milk, caution should be exercised when Alzental is administered to a nursing woman.

Possible side effects:

Abdominal pain, nausea, vomiting.

Fever.

Elevated hepatic enzymes.

Dizziness, headache, meningeal signs, raised intracranial pressure, vertigo.

Reversible Alopecia.

Elevated hepatic enzymes.

Blood and Lymphatic system disorders: Aplastic anemia, bone marrow suppression, neutropenia.

Eye disorders: Blurred vision.

Gastrointestinal disorders: Diarrhea.

General system disorders: Asthenia.

Hepatobiliary disorders: Elevations of hepatic enzymes, hepatitis, acute liver failure.

Musculoskeletal and Connective tissue disorders: Rhabdomyolysis.

Nervous system disorders: Somnolence, convulsion.

Renal and Urinary disorders: Acute renal failure.

Skin and Subcutaneous tissue disorders: Erythema multiforme, Stevens-Johnson syndrome.

Storage Method:

Alzental Suspension: Store at a temperature not exceeding 30°C.

Keep out of the reach of children.

Package:

Carton box contains bottle 20 ml and plastic measuring cup and inner leaflet.